<SEC-DOCUMENT>0001193125-14-110536.txt : 20140321
<SEC-HEADER>0001193125-14-110536.hdr.sgml : 20140321
<ACCEPTANCE-DATETIME>20140321170423
ACCESSION NUMBER:		0001193125-14-110536
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140321
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140321
DATE AS OF CHANGE:		20140321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		14710877

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d698060d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;21, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2 &#150; FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2014, Galectin Therapeutics Inc. (&#147;Galectin Therapeutics&#148;) issued a press release announcing its results of
operations and financial condition for the year ended December&nbsp;31, 2013. Galectin hereby incorporates by reference herein the information set forth in its press release dated March&nbsp;21, 2014 (the &#147;Press Release&#148;), a copy of which
is attached hereto as Exhibit&nbsp;99.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for the historical information contained in this report, the statements made by Galectin
Therapeutics are forward looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics&#148; future financial
performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the
Press Release. For further information on other risk factors, please refer to the &#147;Risk Factors&#148; contained in Galectin Therapeutics&#146; Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013, as filed with the
Securities and Exchange Commission, and its subsequent filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item&nbsp;2.02 is being furnished,
not filed, pursuant to Item&nbsp;2.02 of Form 8-K. Accordingly, the information in Item&nbsp;2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement
filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Businesses Acquired. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Pro Forma
Financial Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Shell Company Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated March 21, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics Inc.</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;21, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack W. Callicutt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jack W. Callicutt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d698060dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g698060img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics Reports 2013 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Norcross, GA (March 21, 2014) &#150; Galectin Therapeutics Inc. (NASDAQ: GALT)</B>, the leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today reported its financial results for the year ended December&nbsp;31, 2013. These results are included in the Company&#146;s Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Many important milestones and objectives were achieved in 2013 and continuing into the first quarter of 2014. During this period, we had
significant activity involving our lead compound, GR-MD-02. We received notification from the U.S. Food and Drug Administration (FDA) that we may proceed with our Phase 1 clinical trial for GR-MD-02 in patients with fatty liver disease (NASH) with
advanced fibrosis. Subsequently, we received FDA Fast Track designation for GR-MD-02 for fatty liver disease with advanced fibrosis, and we completed enrollment of the first cohort of patients in our Phase 1 clinical trial. Additionally, we enhanced
our patent portfolio, and we have raised funds sufficient to finance our currently planned operations through 2015. Looking ahead, we expect to announce the results of the first cohort of patients in our Phase 1 clinical trial in early April
2014,&#148; said Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. &#147;This Phase 1 first-in-man study is evaluating the safety, tolerability, pharmacokinetics and exploratory biomarkers
for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
also is working with Providence Portland Medical Center in planning for an investigator sponsored Phase 1 clinical trial to evaluate the combination of Bristol-Myers Squibb&#146;s Yervoy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(ipilimumab) and the Company&#146;s GR-MD-02 in patients with metastatic melanoma. This trial is based on pre-clinical data obtained in collaboration with Dr.&nbsp;Will Redmond at the center which demonstrated that the combination of immune
checkpoint inhibitors like ipilimumab with GR-MD-02 enhances the antitumor effect in syngeneic mouse cancer models. This trial recently was approved by the FDA and expected to commence in the second quarter of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, the Company had $10.5 million of non-restricted cash and cash equivalents available to fund future operations. In January and
February 2014, the Company received $1.5 million from warrant exercises and $28.2 million in net proceeds from the issuance of common shares through its At Market stock issuance program. The Company believes that the cash on hand of $37.6 million as
of March&nbsp;21, 2014, is sufficient to fund its currently planned operations and research and development through 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2013, the Company reported a net loss applicable to common stock of $21.9 million, or ($1.30) per share, basic and diluted, compared with a net loss applicable to common stock of $10.9 million or ($0.72) per share, basic and
diluted, for 2012. The increase in net loss applicable to common stock is largely due to an $8.8 million or ($0.53) per share one-time, non-cash charge related to modification of certain warrants recorded in the second quarter of 2013 and an
unrelated one-time, non-cash stock compensation charge of $1.0 million or ($0.06) per share recorded in the third quarter of 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expense for the 2013 was $5.7 million, compared with $4.5 million for 2012. The increase in research and development expense in 2013 over 2012 primarily relates to increased costs for our Phase I clinical trial offset somewhat by lower
pre-clinical and drug manufacturing costs. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense for 2013 was $6.4 million, compared with $5.4 million for 2012. The primary
reasons for the increase were non-cash stock-based compensation and legal expense offset somewhat by decreased rent expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin
Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve
cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at
<U>www.galectintherapeutics.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements relate to future events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are
subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding our plans, expectations and goals regarding clinical trials, including our
expectation that clinical data from the first cohort should be available in April 2014, the Company&#146;s plans regarding a Phase 1 clinical trial to evaluate the combination of Bristol-Myers Squibb&#146;s Yervoy<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (ipilimumab) and the Company&#146;s GR-MD-02 in patients with metastatic melanoma, and plans regarding future funding alternatives and the sufficiency of cash on hand to fund future operations
and planned research and development through 2015. Factors that could cause our actual performance to differ materially from those discussed in the <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements include, among others,&nbsp;that
our plans, expectations and goals regarding any clinical trial or any future trials are subject to factors beyond our control and there is no guarantee that we will avoid delays in the development of our drug products or receive FDA approval for any
of our drugs in development. Any current clinical trials and any future trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of a trial could prove time consuming and costly.&nbsp;We may
have difficulty in enrolling candidates for testing, which would impact our estimates regarding timing, and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that
are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from any proposed indications. Plans regarding development, approval and marketing of any of our drugs,
including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully
develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December&nbsp;31,
2013, and our subsequent filings with the SEC.&nbsp;You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B>Jack Callicutt, Chief Financial Officer, 678-620-3186, <U>ir@galectintherapeutics.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yervoy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Bristol-Myers Squibb </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Statements of Operations </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(in&nbsp;thousands,&nbsp;except</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">per share data)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock dividends and accretion costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Modification of warrants</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss applicable to common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Balance Sheet Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable, convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g698060img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g698060img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@"Q`P$1``(1`0,1`?_$`+L````&`P$!`0``````
M```````&!P@)"@$"!00#"P$!``("`P$!``````````````$"`P0%!@<)"!``
M``<``0(#!00%`Q4!`````0(#!`4&!P@`$2$2"3%!(A,*49$R%'&!%1<W818V
MP='A0J+2(S-#LW2EQ5979W<H.!DY&A$``00`!`,%!@('"`,``````0`1`@,A
M,00%41(306%Q@0:1,D*2%`>Q(J'!T5(C,S3P\7*R8W-$%80U"/_:``P#`0`"
M$0,1`#\`LK>I[ZI4]Q-OV(\/.+E&@MSY_P#*V7;P6-9I/23B/I&?0;QXLS5U
MC774>8DBWJD:#1RJBU1.BL[(R<J"HFBB)C$2LYWP4Y'S4)&V+DYZB_*F[ZTZ
M;H.9XF!2U(X^8Q`R)@!1S%TF@PE(DY*1A6+@131<3S^0=N4B`=0"B84P(FF\
MZ^4O.WTT*963O)M#E'E&P:UCF.YMODW5*Q!:E@MWT#3:G6QB-XKE;;0E&TBA
M66IN)!**L<8QB7[*<^0W?-EBN$G($4_0^`=8K28Q<9NI"U[CUK]2?$J6"(FD
MU^YVFF3\!0;^ZR^VR;`6\'?F=<@[:XK#X%TE"R"=:LJ:T#,@*13IF1<D$@E.
M)@$#%*(2)SE(!SFH(4%OH,\K.6?)>1]1J!Y;;&.QVGCOS!D\,JTLWJ-9I$0Q
M@:=%.HY=2)KM6CF+)BG-O6@NU"G.X4*H<2_,,`!UN*%8.$1[]:DYS$R`<%8!
M8[CU7J3XE&"'<>G4GQ*,$.X].I/B48+C/+#!LI>+KSR9C6D_.MY-U"0SAZW1
ME)9M#$:'EW$8Q44*Y>HQ97Z`N#IE,5$%2><0\P=Y$["6!Q59X1/%DAO)?E'B
M/$?.B:KR"T%AG%%5GXFK)3D@TDY`BL]/**)QC%%G#LG[Y4ZA$%%#G`GD223,
M<W8I1'K#N&Z:+;--U-9,AAGVKG=@]-;WZJUQVST]4+M::R0"P#CB3QR2_P`<
M_:RD>PDV#E-XQD635^R=HF\R+IH\03<-G*1A`!,FNBH4Q1[!W`>LD;I3B)Q)
MY9`$>!#A</93;19*B\-?"1C(<)`L1Y$%>SN/4]2?$JC!?,YQ`0#O[0[]_L_L
M=98RD:W?'F56YI$9,'_2HC?4@Y2<P\3TCC!D_#RI5&[WK>9&_L'<5;X1Y*-V
MR-3;U]PG+#(-)F);P$+'-Y559\Z7\Z::8$#\1@`>N>I-?O.CU-->S],RLDTA
M(.`&=^[S7O\`]B?17VQ]4;=OV^_=34ZK3;+MVG$Z^A9&NSG,^7E#@\W,,`&=
MRG=Y;:M9RRGL)KF3MV.GL4BV2!PWJ<"6AU"+>B05%6<4^L$])3-E61_"=4"H
MD]X)!W`>N<T`UL:8_7VU3ND,HQ(]G]P7DWJK<?1>MW&5?HC1:RC;:Y$">HO$
MY3CV2,1$,3A@"6?-*)(7PVJU]XZX\:YGSJ<CD3*&,LU:W&%.HH`"W2EV\;*L
M96-2/V$`4(/O_";MVZWUUE12Z;SSY@Y'<YBA7FNYI%6&%5("R9(&0<M7K1R7
MYK*28.4[&`.&+Q'XDS=BF[>!@`0'HB)C#U-N1[I^P:JLLV!-T_8ME/EUZ0(J
M*3AVB@I\DRE@.0%0(H(AW`0\/8/1$Y?>>5_/7(Y&]*TOC/7]QB&-]O=*H[2G
M5[0HF578M\NJEBS.W3SIS-2;!_7W^CW5&+G%V::?R(Z+?KM@,JD"8$3S/WM[
M!_PQ_P!6V+^]Z(J=_I[7%]R4^J^Y@Z->W"\F[R:,Y'U6AMY`X.DJ]#9B:J8O
M7VL:1?X696D,[?+%%,H`"KU8WM.8>B*]B0"D+V`?`OO\/T^/8``/#HB0C?\`
M&LGY-9A+Y'IZQ)&FS,O4IMTG%S+5C(-IFB7*OWNM/V+T2.@:/(ZQUIJH!@()
MO*!B^'F[@1%+F+RAA>)/&'8^2:]0MFK-\DK"DX&?9G&+V2X6V44=LXR*KT2S
MCD7JC91]*22!5W)TSILFPG7.42D[#641(,43#K7NWJJ0'$&0Y@#4^(,=88;'
M7.[3/$N>KFPM+)&5EE5U+M(T!YM@W1%!#1XRNHJ)+'-4BLPE$Q1^6"?Q]5Z4
M/+^WFI=/4X"<PJ?SZXB8ERWHT')U6!V*K&F352960=2=7FXR3?P%D@'+YJ!&
MTB6,GHIPFDY3*0KA$"*`4OF[!`J@"X='4)GTZHF+J'K2B7V_^S;3`[?;\4QX
M>[VCUE4)^5>]0V^\KN3?(;CSPP=8Q7Z+Q/F8ZB[?R8VP9BQUN1V&1*\67RG(
MLYK5FI;RU*59".4":G7<RW8MUQ^0@@X,'GZH:XDOVJ77/XN>IS/V?G=J?IE<
MGX;-8+DO3*+'ZWENA8[,2+W*MZRV09-WRSR*KUB=/[+1KY7&JICR$2N]D$#I
MHK*(.3$3[#4TP*.C#/>H5HNW\R]/X,<&JGGUKN/'>"B)?E1O^M.I]7),2F++
M\TM:S*!JE158V/4M1DB(JK.6Q)&)CHM-`_SW!U"F2`*8!'79SGE;S-I'.VL\
M*>1^$0U^I6C8]-ZO0.8N"U&\UO*8N1JRSM"?S?5ZY:I2Z-ZI93J-R?D%D)U7
M\V#IN`-@$YS$DU0*.HD(;>?4/NGU#MGQ"QON,\S,X;P@M4UFM+1D-3@<GKU3
MU6U9I*S,T\ETH.9MD[ILB$4Q1=+':(L"MD_EH`3RB)PKB)<PS"J0X8Y)TGK6
M\Q^4G"_A>SV#2^''#GDK0F,G2(S06]RO%RFJO6-+G)J0:UZ3B,VL&=MG-BK$
M2^29E(]/+-'_`,YP<0033+YC8M3H]+K(=/4PC.'>%O[?N>X[3J/J]KNLT^IY
M2.:!,2Q[PI&N47(/DIDW",_)#COE>/Z+;JEBZ.NVVF:)<K-G]>1K$/GHW"<0
MJ"U>K=E7DI9`J!DVC!P=BDHF`%%R4W8!R1HKB``,`&'EDM.4YSD9S)E,ER3B
M23F2>)[4RG@-Z@O.CU)^'.2;GBF0XAD$]9(.9_G]IVSL]%D<ODKK%629BE:Y
MBV=5F6976U0+"/9MQ?3LG,,&:;Y15JU3>G15,G/2AGVJ'2F^FMZCNN<G]UYE
M<-^4>9Y_G/*'A/;:]$7!]D<[,3>6Z53[<@Y5KUTJ9+,3^<D`JH#=,R[)X=82
ME=I]C%,4Y`GDBS=CNJD.I8)FLU5.9;7V1BFSFPUN`G8V-EU44U7T?#27Y.1G
M&3%10AOD$DU(5L9;RAW/\DH#\/AU!KB;3=\9CR^3OAWK-7?J*J9Z:NR<=+9/
MFG`'\LBV',.T!W`[#BJL.O:K9]UT:8NMK?+NCRTLLE"1RRJB\?7H4[LZ49%Q
MC41,DT0;-CE%44@*993S'.)A'OU>`Y(F.;]IS'@L;DP$"V!P+!_##L4EN?\`
MIP;SG4]'77/=YJM7L#9`WY:180LZFJ+=XAV5:NVYCJ,G[8Y%`$4UDSI^8`$`
M`0ZE0N5,^EULMCDWLS/[=4IJ9DG*CR1E).,LKQ^]<JCW46<.%ES'.81_0`>P
M```[=$7@9>E7I3)\R>*:Q1SILWK5T9-.$L":BI6KI)84B*&5`I3*@F)0'V>/
M5<88V2BRH.:,I2G*/3)CR]W[S^;LIMVZ/G22%01`Z8$+V)V`H?+*)>P`/F^$
M>_\`)^KQZQ662A/E#,KB)#N1(.6(R;L\VS71[?I^\?Z_63F**C)IN?N?21^I
M=J?)[2DUH'B5SSG;Q$Q&INB_EZE6KCL<`T:6RM6"3'LRBG%;U.-:/C%6.`!%
M217';RIJ^2Z*\FW.51H50@E`BA#'(8ARJ$$AA$2*$4*/D.0Y!`2B`]A`0]W1
M%0*^J8X^<>\@Y`<!&.*5J$R*V[1.72/U6,S1Z\J"EFKKN_9Y'P]AG(B'?L&W
MY]25G)-)*0%,'"RAU""8P$^$BM>\B]-X>>BCPBT;;8/*V%(RO/TH4C7/\V8M
MV=AT:^3!6-5JT3^T7ZIQ?V&;<$13<23XZATFJ2BZ@G%/L)$UNSU#?^4WI[ZM
MRAYE:O(9I":'Q9O^LTWC!BEJ>T#*\^KEARV9L=,8:UIK)1AH>O6TS)TS4DRJ
M/XNO`Y,9!..4*7SG(O/]-*\20]&/AL@JJ@+ATWU8I">=)!110NQ7DRP(MOA.
M;\N"GQ@`?`!>X^[HB;?].R8RNF^M<BU5("W_`++].!)7N/8AEB38(+&*`"(E
M!7W?:`_9T1--^F=P[(;G"^I'C_)'(,[O.^9/S=M"MT0TVFP]@ML<QL#%=CYU
M"V%HX?)L5K+69(Y3D`$U#K>?Q%0!Z(K1M<XZ\1<?T*IV.J8EQ^SK4)(96+I=
MA@*#0:M?'X$BG"T]'UR4:L&EB=IMZ\DJ=VBV.<I&GF%0`3Z(JY'TY#U[1.:7
MK@XMIR@M]T;\NTK[.-Y(3DFI6L/K1J+5I+)D<B9VO$E-*-%TU0[I_)D$3>PQ
M.B*UE/W.M58\"E89J,AEK1.L:O6T9)ZBS4G;))-WKMA`Q15S%_/2SIK&N%2(
M)^904T#F`.P"/1%67SD1+]65R!.(?XWTV:>*8>/Q=I//A\/#W^0W;[?*/V=$
M2G_57+>;T;MB^'R]]5P;VCV\#:+&F#P$`'OV+W[?R]$4G&[_`/RKUKV?^`UR
M]H@`!_V_O_$1'L`%#WC]G1$S3Z;3X?19X4$,/F\M<T<G8P]C``[#?_`Q>YO(
M8/-[/=T1-)]-9=LI]0_ZXOY<`*4M-XYI*@!1*87",)#E<G\O]OW44#N;]'1%
M/[HO)7),\VW%N/%]F6\'=^1<)I+K*4)-9NA'V^1S="NN+/3VJRJI.]B7A+,#
MMNW_`!.$6RX$[G(!1(H,.2O#[3<4NLN]@JU.V/.'TFX?U>S03%U)?LULX75<
MH1$VC'IK.8N0BS?X(ISD!!8"`8IO'MT1*AA9N>.V6:,B(O2-@KU/!V@2PVV8
M<NHR*AHLH@+DC$SQJB>0?BW*)&Z*!3?&("80*`CT13>U'3*%.W"XY1`W!C8+
MYE$52UM!@47A'TS5D;HTDEZD-G.D7R,Y:Q1\*N[*B<06%$`5$H$43$Q%1PY#
M<\>:E=Y<;14H3E%LT76(3D?=*Y%0+&W.&\9'0+/1WT>TB638J1@18M8XH($3
M\0!,`#KP_<]]W>&^SKZQ^GC?*(CW<Q&?@OL%Z)^Q/VCW7[4[7NUVS4'=]1L5
M$YVRQ)NLTT9FUL/B)+?I5\R-*H5@T!5053BW1,900[&,)DRF$3>(]S"(^(^\
M>O7X$FJ$CF81/M"^/Y]^9``B9R(`#``DL/(8/V\%T>MU0D3Y`\=,-Y3YA/XU
MR%RVG:[FEE*0):IW2)0DV`KI`<&\DP5.4'D1,LOF&%N\:*(ND1,/D4+W'H;8
M`L<T9,]S#TZYO!H1O1\)YP<QZ'EC!%-C`9K8[9FNS1E+A4410:0-*LNR9E=;
MM"PL<F!2M6ZDDY(W(4"D^$`#J.M#O1BO-%>D7P<=7U?8=ERM7E;M[HT8*VS<
MJYU[M5W:I0K@CF'8UU&P%)4J5&1#DHK-6L)%QS=NJ(F*7S"(].M7WHQ3G.7O
M$?$.<>`73C9R&K*]IS.\I1YI%LPD5X:<BI6'>(R4)8J[--BF6B9^$DD"+-U@
M*<O<!*<ATS&(+K0[T8IHV(^DMA>69=!XKHVH\B^5N3U*!)5Z3FG)K41N^<5&
MOM8\8J,CF-%A(>L5Z9-"QYQ1CUI=*25CBE)^5%$2$$KK0[T9%CC#Z.F*<1JL
M[I>0[QRS:5F)CKE$9#$RFM1$@CQZC=&L;"S7Q/&A6IH)Q<G:'<:D@X?R:<DZ
M(S%1-$R0K*F,ZT.]&*YW'OTS.-/IG3FA;ID6F<P%/WCWAE:-5I;W27FL1.PW
MVSRJ\(RG+14%:J,G+3SF6LYU#N6SAJ)!-YUC_)3[!BNU=5`>8D?`.MG1Z2W7
M6]&DQ$N4EY'E``#XDI/[EA_%G7>5=KY+\?+9R:XF<LVU]BN-^UZ]BE,CVE>N
MMD/#1-AA*9OU'N%?M^<W9%C'2,>HVF%V(*-C*HD_.@80`,&DW33ZR4HU"QX3
MY"\2&DN:O]+;CIZH6V3T[6:7ZB(Z@<UGM`X]V:>'Q;R?-9RP36_26H:UR-V&
MGS=_Q;]Y.WM(R'=Y^ZK4Z,#H-7S;/*[7:I2Z*TF)B&2)(/(^.![*IH)E5=*H
M%*0,].LHO+0)YN>46(8O$`G\0RXO<]LU.U=/ZHP/5IC9'ED)?EDX#MD<#@BI
MO_IJ8GM.]0/+FA7'4.+G+:#A#UD_('`)>&@[%=:D5-NW"I:O5K-"66CZ;6VY
M&B944I2.470!),"JE!)+RY#J*A5UB?RAO'$MEXKB>M!@<03V-C[$LN8\6@KM
M\@-2V;;-4Y*:%3&L@A29?4TJ-!5G/5)MFM&R<W3<ZS:HT^IQMIEXMTJQ6F7:
M+N2*Q54;HK)HK+%/E)$9],G\S*T+:YU&X%H``E\,P)#]!Q[\$A7)_P!,;+>0
MO)O.N:='V#<.,/)_/ZDMFRFLX/*UAJ\NN<.W"ZQJ5>:[=ZO;ZM/Q[==TH+=8
MS/YJ8"`>8WRTOESAQ&"B%U5@!C(<IR/9X/Q14Y*^D-QTY:8]!X'N&M<KK/D3
M)=K+S--3W1\#70+PWEY2P+Z%?9-U`O9N?M\C.3"KA3NY2CT#%2*V:(D13(5A
MQ#*]<X6D")#D$@<6S9*I9.`M$L/&%YQ.L/)'ENXRA=FM7I:46V1BWODKGSFK
MHTQSFTG>@IZ4BXHYXKN4Z'@[545-\QP8IO+U64HQYG.,6?S6*N^%UIIK$S,$
MC(L>4.6/;@47N$_!K&N$]*T3C-Q[T?E6RSRNPR,3#5W1+8YL57HCF\HR5C<3
MV*3TM4V[4)@CQ^HH[^2N\:,7H@4Z!#F$#6!!,A^ZS\,5MV0%==%DIP;41D8C
MFQ'(6(D,XGM`.8R1"P[T@>/G'[DK=.7&?;1R]+NNF.HYSKUJL>WDG66M-HYX
MU=M(6_P[VI!'R4,F+),A$&Y&ID$B_+1%,!$.K&+1$GBQ[UKFV(=G+0YBPR'`
M]_:W!5_?K'9^;K*?IQ6BK3$M7+)7KCN\W7;!`R#J(FX&:C(W,7<;+Q$HR6;O
M(^2CG:)5454SE.10H"`]4<.RO`BRH6Q]P^WV*-;BA]67SXPVIQ=)W:@9GRM8
M0[5%FSNEH>RV>ZBY;-TB)H?M^P5MI)U^Q.O+X'<K1A'2HAYE%#F$3#*E'+D?
M]79S>U*JR54P/%\AXU.I5JJS-?#2,QK-VBDURF1.I`(SL=`U*/?%2.(IN%V#
MP4E``P$[AX$4FOT?]ZNVH5_U(]&TFVV*^7ZZ;/B4_;;E;91U-62R3;ZGW)1W
M)2TF\567=+G'L0.XE*1,I2$*4A2@!%%?R?`1YL[\(>[E3?0_7^])^']7K\^[
MG799OELH`L-7/_.5]W/MM&R'V:V24XR$?^@TLL1F/I8AQYA?I`,/%DS_`-%;
M_P"9)U[A#^37_MQ_`+X3R!C(QEF)$>PKV];RHM1]H]:L_?/BI"QU52AT1#HB
M'1$.B+Q.2?,*4HI&4#Q$0[>`^'L-X=^WO\/'OUMSG34.8#F\,2J2-D8\])(L
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MGBG(Y]R7G<NI$#/`A>(2/BWNM0%T4>R]RS65CI6-707D6ZJZQGHN6[52)!LU
M40$Z?RPU;=)JCH)PD)G62,7PS(D2XQX?CDI_[C9)^H]/,5Z:K9JM5*8DW,3"
M5<8@3#$M$QRXR)"-_(W,=YAYJMP>!9SK;B$J%<SZZ0UP:ZG)S+YU+);HWLNA
M4!.-M=YCTHJ44HJCHJCAW^T0DF;A.,0_+H(&-UFNHU0OA;4)$1,#QR+D?M6O
MLNY[37I-3J-9*GZBSK0C7*`#?P.6N?NY"?NY8XHF0<3J]SV_:$LU;ZT2U5'G
MMF[A"V/+G)N,\H^,MZ-CEMUZERL0^LR[%5C-P4I*($B$&)_F2<@@J@H0J1E"
M4H&JG9=$&7+9JH2_P`$$@\/!9;]5H-)M-$=;&B6CGMES0C`=25THSC5:&BY`
MF(EP<&.&*--?P[DG(Y=O["U2>RGWV9S_`)&5J.EF]R9PF66"=FK5+36(V&FO
M(Y^E,L)B+AQCF[!8AF@Q*)7#9SYP$O?9KIU)IO,R1/'E[_#CW++K]W].3W/;
MSIM+IH[+"V@EB]L:HL+HV#L,\>+X,B_=<QY!:;1N3;&4R[8P:VB"X<6:CUZ<
MN35!U-S><S<4XVV/@FC.Y'0KDO((Q)A5:&5;-9,Q2*@/F4ZC4:;52E9RB3$0
M;O('YE%&Y[7H=RTDZ;:.C"[5DD1!:%@_A"1Y<6##M8N.*/.@4KDP]N'(MSG]
M;U2/I4K;>(<]#0[NSD1>V+-:PD9'D)3\Z<.K.\/7K')Q`II.4@69ED3$4*FM
M\U7YG6Q*G5_Q8X](B#<6$0)#B[_K7'[=K-LK^CGK9T3E&.IYG`:,Y2/3,@V3
M,Q9@C-;,_P!B0T3`)7)ZYK3.BURRF/:Z=?+'(O(MW7['IK:4E)<TZC<36.M3
MU1BRK.&<?(DEXEY!#^S#))*BF8O'ZK1Z@W4RHYQ6(?F=\W?\/V+%IM1H9Z76
M?7STYU<H#E,6#M`````"6.;,7Q40'U.'IU\R.?L3PV:<2L>6U5;+YC9'5Z*%
MJJ%5"$;6J.H[:#,8;5-0Y78OE(=P'9`5!3`GQ@'<.NR4F/1`^(+HL!(-'*#?
MK_8JG@?3C^LD(`(\/UP'_JUD'N\/]]^K.LBS_P#G']9(/$.("P"'B`CK60"'
M?W=P"[]Q#OT=%;E^F)]/?E]P#H'+^%Y:Y&KE$GIE\R:8I+92TU*T!-1U;K%E
M83+D%JI,S"33\H]D$B>584S&`W<`$/'H91&99$Q'>?2MY\VSE7L6A5WCY+R=
M,LO(.XW*%EBVJFHIOZY)7YY-1\D5JM-(O$TUX]0JGD,4JA0'L(>;PZ\?U/IS
M?;-TLNKC+HRU,Y`MARF9(+\&7U?]&_\`TG]E=H^VNU^G=?N$CO-&R446`TV&
M,+85",HORL6E@",#FKN\=Y_R+4%$SI'*@D4R:A1*<@E3*42F[^T0$/;[^O4S
M7.J,:YD2G&$02/!?*"%T=1S70!$)2D0#$P+.<XEB%T.MI2L?=UBE[Q]S-$/N
MZCY%*'W=/D1#[NGR(A]W3Y$0^[I\B(?=T^1%L'6Q'W1EY*J'5D6!_5^OK%9V
M9>:D+YG_``_Y/\1/Q_A_$']U]G\O6"60_E^\,T.29;Q8_B)RT_\`'_\`CF'\
M&_Z5_P!'X_\`CG_S/_V=^6ZXK0_S;OZ3W_@SS^/O7;O4O]#MG_L/Z/\`Y'N?
M^/\`Z7ZT]7[NN7^1=26W6R,E5#J46!_5^OK#9G\/FI"Q]W6/Y%*'W=/D1#[N
>GR(A]W3Y$6W6R,@JK4?U=89^]\/FI"VZR^Q0O__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
